Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model

References

• Choy EHS, Panayi GS. Mechanisms of disease: cytokine path-ways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16.
   PubMed Web of Science ®Google Scholar
• Taylor PC. Anti-TNF-a therapy for rheumatoid arthritis: an update. Intern Med. 2003;42:15–20.
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167–79.
   PubMed Web of Science ®Google Scholar
• Du Pan SM, Dehler S, Ciurea A, Ziswiler H, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discon-tinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61:560–8.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, Symmons DPM, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor a agent to a second anti-tumor necrosis factor a agent in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:13–20.
   Google Scholar
• Nagashima M, Matsuoka T, Saitoh K, Koyama T, Kikuchi O, Toshino S. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfa-salazine, bucillamine in 1358 Japanese patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:260–7.
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Saito S, Yamanaka H, Akizuki M, Kondo H, Ko-bayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15:323–8.
   Google Scholar
• Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated solu-ble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 2000;43:2648–59.
   PubMed Web of Science ®Google Scholar
• Daans M, Lories RJU, Luyten FP. Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease. Arthritis Res Ther. 2008;10:R115.
   Google Scholar
• Hayashi M, Matsunaga K, Okahara A, Mita S. Effect of bucill-amine (5A96) on type II collagen induced arthritis in rats. J Rheumatol. 1991;18:691–5.
   PubMedGoogle Scholar
• Hashimoto K, Lipsky PE. Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites. J Rheu-matol. 1993;20:953–7.
   PubMedGoogle Scholar
• Hirohata S, Lipsky PE. Regulation of B cell function by bucill-amine, a novel disease-modifying antirheumatic drug. Clin Immunol Immunopathol. 1993;66:43–51.
   PubMedGoogle Scholar
• Hirohata S, Lipsky PE. Comparative inhibitory effects of buc-illamine and fi-penicillamine on the function of human B cells and T cells. Arthritis Rheum. 1994;37:942–50.
   PubMed Web of Science ®Google Scholar
• Aono H, Hasunuma T, Fujisawa K, Nakajima T, Yamamoto K, Mita S, et al. Direct suppression of human synovial cell prolif-eration in vitro by salazosulfapyridine and bucillamine. J Rheu-matol. 1995;22:65–70.
   Google Scholar
• Matsuno H, Sugiyama E, Muraguchi A, Nezuka T, Kubo T, Matsuura K, et al. Pharmacological effects of 5A96 (bucillamine) and its metabolites as immunomodulating drugs-the disulfide structure of 5A96 metabolites plays a critical role in the phar-macological action of the drug. Int J Immunopharmacol. 1998;20:295–304.
   PubMed Web of Science ®Google Scholar
• Nagashima M, Yoshino S, Aono H, Takai M, Sasano M. Inhib-itory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells. Clin Exp Immunol. 1999;116:360–5.
   Google Scholar
• Amersi F, Nelson SK, Shen XD, Kato H, Melinek J, Kupiec-Weglinski JW, et al. Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury. Proc Natl Acad Sci USA. 2002;99:8915–20.
   PubMedGoogle Scholar
• Tsuji F, Seki I, Aono H, Odani N, Mizutani K, Okamoto M, et al. Bucillamine mechanism inhibiting IL-1/3-induced VEGF pro-duction from fibroblast-like synoviocytes. Int Immunopharmacol. 2007;7:1569–76.
   PubMed Web of Science ®Google Scholar
• Old K, Tsuji F, Ohashi K, Kageyama M, Aono H, Sasano M. The investigation of synovial genomic targets of bucillamine with microanay technique. Inflamm Res. 2009;58:571–84.
   PubMedGoogle Scholar
• Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-a promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001;167:6821–6.
   PubMed Web of Science ®Google Scholar
• Odani N, Mukai Y, Tsuji F, Aono H, Okamoto M, Sasano M. Combination effect of bucillamine and methotrexate on rat type II collagen-induced arthritis model. Inflamm Regen. 2007;27:516–21.
   Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–147.
   PubMed Web of Science ®Google Scholar
• Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin-1 receptor antagonist-deficient mice. J Exp Med. 2000;191:313–20.
   PubMed Web of Science ®Google Scholar
• Cook AD, Braille EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 2001;3:293–8.
   Google Scholar
• Plater-Zyberk C, Joosten LA, Helsen MM, Hepp J, Baeuerle PA, van den Berg WB. GM-CSF neutralisation suppresses inflam-mation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis. 2007;66:452–7.
   Google Scholar
• McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, et al. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med. 2001;194:873–82.
   PubMed Web of Science ®Google Scholar
• Burmester G, Wagner F, Feist E, Sleeman M, Grove G, White B. CAM-3001, a novel human monoclonal antibody against GM-CSF receptor-a, in subjects with rheumatoid arthritis (RA): results of a first-time in human study. Ann Rheum Dis. 2009;68[Suppl 31:124.
   Google Scholar
• Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16:249–84.
   PubMed Web of Science ®Google Scholar
• Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999;42:1635–43.
   PubMed Web of Science ®Google Scholar
• Tsuji F, Yoshimi M, Katsuta O, Takai M, Ishihara K, Aono H. Point mutation of tyrosine 759 of the IL-6 family cytokine receptor, gp130, augments collagen-induced arthritis in DBA/1J mice. BMC Musculoskelet Disord. 2009;10:23.
   PubMedGoogle Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619–26.
   PubMedGoogle Scholar
• Aono H, Hasunuma T, Fujisawa K, Nakajima T, Yamamoto K, Mita S, et al. Direct suppression of human synovial cell prolif-eration in vitro by salazosulfapyridine and bucillamine. J Rheu-matol. 1996;23:65–70.
   PubMedGoogle Scholar
• Brenann FM, Chantry D, Jakson A, Maini RN, Feldmann M. Inhibitory effects of TNFa antibodies on synovial cell interleu-kin-1 production in rheumatoid arthritis. Lancet. 1989;2: 244–7.
   Google Scholar
• Butler D, Maini RN, Feldmann M, Brenann FM. Blockade of TNFa with chimeric anti-TNFa monoclonal antibody, cA2 reduces (IL-6 and IL-8) release in RA MNC cultures. A com-parison with IL- lra. Eur Cytokine Netw. 1995;6:225–30.
   PubMed Web of Science ®Google Scholar
• Haworth C, Brenann FM, Chantry D, Turner M, Maini RN, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest. 1991;83:876–82.
   Google Scholar